BioSpace News Archive

Locust Walk, a global life science transaction firm, today announced the appointments of Neil Higgins, Managing Director of Financing, and Turner Grant, Senior Vice President of Financing

DiA Imaging Analysis, the developers of artificial intelligence (AI) powered ultrasound analysis solutions, has announced today the presentation of two studies assessing the performance and accuracy of the company’s LVivo EF AI-based solution that generates fully automated Left Ventricular (LV) Ejection Fraction (EF)

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC)

The Environmental Science business of Bayer is honored to have contributed $45,000 toward the development of the new Cook Museum of Natural Science that opened on June 7 in Decatur, AL.

Working prototypes of inventions that enable fresh food production, address gaps in rural healthcare and improve health and safety of firefighters are just some examples to be seen at the 13th annual EurekaFest event

The U.S. House of Representatives just voted to repeal the prohibition on the use of federal funds to create a “unique patient identifier,” which former Representative Ron Paul, M.D., sponsored in 1998.

IASO Biotherapeutics (IASO BIO), one of the top biotechnology innovators, announced their potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the American Society of Clinical Oncology (ASCO) Annual Meeting 2019

ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204.

Arizona’s only “Best Children’s Hospital” is one of just 10 programs nationwide to earn three-star designation

Suicide is the 10th leading cause of death in the United States and the 14th leading cause of death in New Jersey.